Monte Rosa Therapeutics (GLUE) outlined anticipated 2025 milestones ahead of its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company’s presentation will focus on ...

Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S.

Monte Rosa Therapeutics, a biotechnology company focused on developing precision medicines to degrade disease-causing proteins, announced today the cl ...

About Monte Rosa Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins.

Wells Fargo analyst Derek Archila downgraded Monte Rosa Therapeutics (GLUE) to Equal Weight from Overweight with a price arget of $11, down from $14.

--Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader- based medicines, today announced that Markus Warmuth, M.D., Chief Executive ...

That’s why she founded the Ultra Tour Monte Rosa, a 93-mile mountain ultramarathon encircling Switzerland’s stunning Monte Rosa massif.